Effectiveness of alpha-lipoic acid in patients with neuropathic pain associated with type i and type II diabetes mellitus: A systematic review and meta-Analysis

Vista sencilla de ítem
dc.contributor.authorOrellana-Donoso, Mathias
dc.contributor.authorLópez-Chaparro, Michelle
dc.contributor.authorBarahona-Vásquez, Marisol
dc.contributor.authorSantana-Machuca, Andrés
dc.contributor.authorBruna-Mejias, Alejandro
dc.contributor.authorNova-Baeza, Pablo
dc.contributor.authorValenzuela-Fuenzalida, Juan José
dc.date.accessioned2025-01-27T13:35:03Z
dc.date.available2025-01-27T13:35:03Z
dc.date.issued2023-11
dc.descriptionIndexación: Scopus
dc.description.abstractBackground: This systematic review explores the most current evidence regarding the mechanisms of neuropathic pain in patients with different types of diabetes and how this pain affects different functional and structural components of the neuroanatomical pain pathways. The review also seeks to provide guidelines for the best approach and treatment for patients experiencing this type of pain. The objective is to determine the effectiveness of alpha-lipoic acid (ALA) in improving functional and symptomatic outcomes in patients with diabetes mellitus type I and type II. Objective: To determine the effectiveness of alpha-lipoic acid (ALA) in improving functional and symptomatic outcomes in patients with diabetes mellitus type I and type II. Methods: We systematically search MEDLINE (via PubMed), EMBASE, SCOPUS, the Cochrane Central Register of Controlled Trials, the Cumulative Index to Nursing and Allied Health Literature, and Web of Science databases. Results: The findings of this review show that different forms of ALA do not present statistically significant changes for any of the scales included, including total symptom score (standardized mean difference [SMD] =-3.59, confidence interval [CI] =-4.16 to-3.02, and P <.00001), neuropathy impairment score (SMD =-1.42, CI =-3.68 to 0.84, and P =.22), and neuropathy symptom checklist (SMD =-0.09, CI =-0.15 to-0.02, and P =.01). Conclusion: In comparison to the use of a placebo, the findings suggest that ALA does not exhibit significant differences in terms of pain reduction and different functional scales. Moreover, no specific dosages are identified to support the use of ALA for the reduction of neuropathic pain. © 2023 Lippincott Williams and Wilkins. All rights reserved.
dc.description.urihttps://journals-lww-com.recursosbiblioteca.unab.cl/md-journal/fulltext/2023/11030/effectiveness_of_alpha_lipoic_acid_in_patients.100.aspx
dc.identifier.citationMedicine (United States). Volume 102, Issue 44, Pages E35368. 3 November 2023
dc.identifier.doi10.1097/MD.0000000000035368
dc.identifier.issn0025-7974
dc.identifier.urihttps://repositorio.unab.cl/handle/ria/63287
dc.language.isoen
dc.publisherLippincott Williams and Wilkins
dc.rights.licenseAttribution 4.0 International Deed (CC BY 4.0)
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectAlpha-lipoic Acid
dc.subjectDiabetic Polyneuropathy
dc.subjectNeuropathic Pain
dc.subjectPharmacology
dc.subjectPolyneuropathy
dc.subjectType I diabetes mellitus
dc.subjectType II diabetes mellitus
dc.titleEffectiveness of alpha-lipoic acid in patients with neuropathic pain associated with type i and type II diabetes mellitus: A systematic review and meta-Analysis
dc.typeArtículo
Archivos
Bloque original
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
effectiveness_of_alpha_lipoic_acid_in_patients.100.pdf
Tamaño:
1.35 MB
Formato:
Adobe Portable Document Format
Descripción:
TEXTO COMPLETO EN INGLÉS
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar
Colecciones
FM - Artículos de Revista